skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations

Original Research

(2756) Views  (978) Full article downloads

Authors: Kai-Michael Beeh, Bettina Hederer, Thomas Glaab, Achim Müller, Maureen Rutten-van Moelken, et al

Published Date February 2009 Volume 2009:4 Pages 119 - 125
DOI: http://dx.doi.org/10.2147/COPD.S4676

Kai-Michael Beeh1, Bettina Hederer2, Thomas Glaab2, Achim Müller2, Maureen Rutten-van Moelken3, et al

1insaf–Respiratory Research Institute, Wiesbaden, Germany; 2Boehringer Ingelheim, Ingelheim, Germany; 3Institute for Medical Technology Assessment, Erasmus Medical Centre, Rotterdam, The Netherlands, et al

Abstract: Currently available long-acting inhaled bronchodilators (tiotropium, salmeterol, formoterol) have demonstrated beneficial effects on exacerbations in placebo-controlled trials. However, there have been no direct comparisons of these drugs with exacerbations as the primary outcome and consequently COPD treatment guidelines do not indicate a preference for either bronchodilator. Therefore, an international, randomized, double-blind, double-dummy, parallelgroup clinical trial has been designed to investigate the comparative efficacy of 2 long-acting bronchodilators tiotropium 18 μg daily and salmeterol 50 μg bid on exacerbations. The trial will include at least 6800 randomized patients with diagnosis of COPD, 10 pack-year history of smoking, post-bronchodilator FEV1 ≤ 70% predicted, and a history of exacerbations in the previous year. The primary endpoint is time to first COPD exacerbation. Secondary endpoints include number of exacerbations and time to premature discontinuation of trial medication. The trial has been designed to address several of the challenges in studying exacerbations in a controlled trial by a symptom and event-based definition of exacerbations, frequent follow-up contacts, selection of time to first event as the primary endpoint and using exposure adjusted analysis when examining number of events. Other challenges in designing exacerbation trials such as differential discontinuation and follow-up of discontinued patients are discussed.

Keywords: chronic obstructive pulmonary disease, exacerbation, salmeterol, study methodology, tiotropium








Readers of this article also read:

Mechanisms of improvement of respiratory failure in patients with COPD treated with NIV
Preferential recruitment of neutrophils by endothelin-1 in acute lung inflammation induced by lipopolysaccharide or cigarette smoke
Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT® studies
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes
A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD
Tiotropium HandiHaler® in the treatment of COPD: A safety review
Budesonide/formoterol combination in COPD: a US perspective
Development and implementation of treadmill exercise testing protocols in COPD
In search of parsimony: reliability and validity of the Functional Performance Inventory-Short Form
  • Journal Indexing

    See where all the Dove Press journals are indexed

  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio